222 related articles for article (PubMed ID: 18703645)
1. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist.
Fujitaki JM; Cable EE; Ito BR; Zhang BH; Hou J; Yang C; Bullough DA; Ferrero JL; van Poelje PD; Linemeyer DL; Erion MD
Drug Metab Dispos; 2008 Nov; 36(11):2393-403. PubMed ID: 18703645
[TBL] [Abstract][Full Text] [Related]
2. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
Erion MD; Cable EE; Ito BR; Jiang H; Fujitaki JM; Finn PD; Zhang BH; Hou J; Boyer SH; van Poelje PD; Linemeyer DL
Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15490-5. PubMed ID: 17878314
[TBL] [Abstract][Full Text] [Related]
3. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist.
Cable EE; Finn PD; Stebbins JW; Hou J; Ito BR; van Poelje PD; Linemeyer DL; Erion MD
Hepatology; 2009 Feb; 49(2):407-17. PubMed ID: 19072834
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
Boyer SH; Jiang H; Jacintho JD; Reddy MV; Li H; Li W; Godwin JL; Schulz WG; Cable EE; Hou J; Wu R; Fujitaki JM; Hecker SJ; Erion MD
J Med Chem; 2008 Nov; 51(22):7075-93. PubMed ID: 18975928
[TBL] [Abstract][Full Text] [Related]
6. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
8. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
11. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.
Ito BR; Zhang BH; Cable EE; Song X; Fujitaki JM; MacKenna DA; Wilker CE; Chi B; van Poelje PD; Linemeyer DL; Erion MD
Br J Pharmacol; 2009 Feb; 156(3):454-65. PubMed ID: 19183199
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
14. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
Fukano Y; Kawazu K
Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
[TBL] [Abstract][Full Text] [Related]
17. Liver-targeted drug delivery using HepDirect prodrugs.
Erion MD; van Poelje PD; Mackenna DA; Colby TJ; Montag AC; Fujitaki JM; Linemeyer DL; Bullough DA
J Pharmacol Exp Ther; 2005 Feb; 312(2):554-60. PubMed ID: 15340017
[TBL] [Abstract][Full Text] [Related]
18. Prodrugs of perzinfotel with improved oral bioavailability.
Baudy RB; Butera JA; Abou-Gharbia MA; Chen H; Harrison B; Jain U; Magolda R; Sze JY; Brandt MR; Cummons TA; Kowal D; Pangalos MN; Zupan B; Hoffmann M; May M; Mugford C; Kennedy J; Childers WE
J Med Chem; 2009 Feb; 52(3):771-8. PubMed ID: 19146418
[TBL] [Abstract][Full Text] [Related]
19. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.
Choo EF; Driscoll JP; Feng J; Liederer B; Plise E; Randolph N; Shin Y; Wong S; Ran Y
Xenobiotica; 2009 Sep; 39(9):700-9. PubMed ID: 19552528
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent pharmacokinetics and disposition of bisphosphonic prodrug of diclofenac based on osteotropic drug delivery system (ODDS).
Hirabayashi H; Sawamoto T; Fujisaki J; Tokunaga Y; Kimura S; Hata T
Biopharm Drug Dispos; 2002 Nov; 23(8):307-15. PubMed ID: 12415571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
